Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. D‘Urzo, B. Make, E. Kerwin, L. Rekeda, E. Garcia Gil, C. Caracta, B. Maurer (Toronto, Canada; Denver, Medford, Jersey City, United States Of America; Barcelona, Spain). ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients. Eur Respir J 2011; 38: Suppl. 55, 3998

Member's Comments

No comment yet.

Related content which might interest you: Twice-daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010 ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice-daily aclidinium bromide Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 ACCORD COPD I: Twice-daily aclidinium bromide improves quality of life and dyspnea in COPD patients Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010 Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: A phase IIIb study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysis Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Pooled analysis of twice-daily aclidinium bromide in COPD patients: Dyspnea and health status in the ACCORD-COPD I and ATTAIN trials Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study Source: Annual Congress 2009 - New bronchodilators Year: 2009 Efficacy and safety of extrafine glycopyrronium bromide pMDI (CHF 5259) in COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Long-term efficacy of twice-daily aclidinium bromide in COPD patients: A one-year study Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 Efficacy and safety of umeclidinium/vilanterol compared with umeclidinium or tiotropium in COPD Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Cardiovascular safety of qva149, a novel combination of indacaterol and glycopyrronium, compared with indacaterol and placebo in patients with COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009 Lung function efficacy of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Two 48-week studies Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Cardiovascular safety of salmeterol in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 240s Year: 2002 Effects of twice-daily aclidinium bromide in COPD patients: A long-term extension of ACCORD-COPD I Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012